Please login to the form below

Not currently logged in

bluebird bio’s beta thalassaemia gene therapy Zynteglo scores promising long-term data

Results presented at annual American Society of Haematology (ASH) meeting

bluebird bio has revealed some long-term data for its gene therapy betibeglogene autotemcel, which is marketed as Zynteglo in the European Union.

bluebird bio announced the new long-term data at the annual American Society of Haematology (ASH) meeting, reflecting up to six years of safety and efficacy data for the gene therapy in patients with transfusion-dependent beta thalassaemia (TDT).

Zynteglo, or beti-cel, is a one-time gene therapy designed to add functional copies of a modified form of the β-globin gene to a patient’s blood stem cells.

This gives patients the potential to produce haemoglobin (Hb) A, which is a gene therapy derived adult Hb.

This is particularly important as TDT patients have mutations in the β-globin gene that cause reduced or significantly reduced Hb levels. This means that people living with TDT need chronic blood transfusions to maintain adequate Hb levels in order to survive.

Among 32 patients enrolled in the 13-year, long-term LTF-303 study, 64% of patients treated in the phase 1/2 portion and 90% in the phase 2 portion achieved transfusion independence (TI).

In bluebird bio's studies of Zynteglo, TI is defined as no longer needing red blood cell transfusions for at least 12 months, while maintain a weighted average Hb of at least 9 g/dL.

In the LTF-303 study, all patients who achieved TI remained free from transfusions , with the median duration of ongoing TI coming in at 39.4 months.

bluebird bio also revealed data from 24 paediatric patients who were treated with the gene therapy in the phase 3 Northstar-2 and Northstar-2 studies, reflecting a median follow-up of 15.5 months.

Across these studies, following treatment with Zynteglo, 87% of evaluable patients under the age of 16 years achieved TI. bluebird bio added that as of 3 March 2020 these patients continued to be free of transfusion for a median duration of 14.9 months.

“All of the patients in our phase 3 studies who achieved transfusion independence have maintained it, with the durability of the treatment effect underscored by patients from our earlier studies reaching their five-year anniversaries of freedom from transfusions,” said David Davidson, chief medical officer, bluebird bio.

“Moreover, transfusion independence has been observed in paediatric, adolescent and adult patients and across genotypes – suggesting outcomes with this gene therapy may be consistent regardless of age or genotype,” he added.

Article by
Lucy Parsons

9th December 2020

From: Research



PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs


Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

#DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
Women are largely prescribed exactly the same treatment regimens as men, with no account for the underlying differences in physiology and drug metabolism between the sexes....
Good design saves lives
Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
Why you must understand the pricing of patient recruitment companies
Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...